The potential toxicity to neonates of multivitamin preparations used in parenteral nutrition.
This study compares two groups of infants weighing less than 1500 g at birth. In the propylene glycol (PG) group, 30 infants received MVI-Concentrate containing 300 mg of PG daily with their intravenous nutrition (ivn), and vitamin E, 50 mg/week by intramuscular injection. In the mannitol group, 30 infants received MVI-Pediatric (containing 245 mg mannitol), 65% of a vial/day. Serum and urine osmolality, serum PG, blood-urea-nitrogen, creatinine, sodium, and glucose were measured on days 0, 2, 5, 12, 19, 26, 33 and 40 of ivn. Weight, urine output, and fluid intake were measured daily. Vitamin E levels were measured on days 5, 26, and 33 of ivn. There were no significant differences between the groups in birth weight, gestational age, sex, age, or weight at start of ivn. Our results indicated that neither MVI-Concentrate nor MVI-Pediatric was associated with a clinically significant diuresis. MVI-Pediatric, 65% of a vial/day, may produce higher than desirable blood levels of vitamin E, and use of drugs containing PG can produce significant blood levels of PG, in very low birth weight infants.
D004231:Diuresis / Q000187:drug effects; D006801:Humans; D007230:Infant, Low Birth Weight / Q000097:blood; D007231:Infant, Newborn; D008353:Mannitol / Q000009:adverse effects; D010288:Parenteral Nutrition / Q000009:adverse effects*; D011092:Polyethylene Glycols / Q000009:adverse effects; D014810:Vitamin E / Q000008:administration & dosage / Q000097:blood; D014815:Vitamins / Q000008:administration & dosage*
D014815:Vitamins; D014810:Vitamin E; D008353:Mannitol; D011092:Polyethylene Glycols